1. What Is the Growth Hormone Market?
The Growth Hormone Market covers the recombinant human growth hormone preparations used to treat the growth hormone deficiency in children and adults. The preparations also treat the short stature conditions including Turner syndrome, Prader-Willi syndrome, and the small for gestational age child who fails to catch up, and the wasting in AIDS and the short bowel syndrome. The somatropin subcutaneous injection replaces the pituitary growth hormone secretion. The GH deficiency from the pituitary tumour, the pituitary surgery, the cranial irradiation, or the congenital pituitary hypoplasia reduces the secretion below the level that the normal growth and the metabolic function require. Acromegaly treatment uses the somatostatin analogues octreotide and lanreotide that suppress the GH hypersecretion from the pituitary somatotroph adenoma. The GH receptor antagonist pegvisomant blocks the GH receptor at the peripheral target tissue. The dopamine agonist cabergoline suppresses the GH secretion in the subgroup with the mixed GH and prolactin-secreting adenoma. The GH market is advancing with the once-weekly somatropin formulations somapacitan and lonapegsomatropin that provide the weekly injection alternative to the daily subcutaneous somatropin. The weekly injection reduces the injection burden that the daily injection creates.
2. Growth Hormone Market Size & Forecast
3. Emerging Technologies
- Once-weekly growth hormone somapacitan Ngenla Phase III REAL trials demonstrated non-inferior height velocity versus the daily Norditropin somatropin at 26 weeks in GH-deficient children. The trials also showed the equivalent adult body composition and IGF-1 normalisation. The weekly alternative reduces the injection frequency from 365 to 52 injections per year. The patient preference and the adherence advantage of the less frequent injection substantiate the weekly formulation.
- GH receptor antagonist pegvisomant Somavert for the acromegaly that does not achieve the IGF-1 normalisation with the somatostatin analogue alone achieves the 97 percent IGF-1 normalisation rate in clinical practice. The competitive GH receptor blockade prevents the peripheral GH signalling without reducing the GH level. The somatostatin analogue reduces the GH level at the pituitary.
- Paediatric GH therapy monitoring uses the IGF-1 standard deviation score to confirm the adequate GH replacement and the height velocity response at 6-month intervals to assess the growth response. The GH dose may need adjustment when the height velocity falls below the expected velocity. The expected velocity accounts for the treatment duration and the baseline height deficit.
- Long-acting GH TransCon lonapegsomatropin Phase III PATHFINDER trial demonstrating non-inferior annualised height velocity versus daily Genotropin with the once-weekly 0.24 mg/kg dose provides the prodrug approach. The transient connector releases the native GH from the carrier molecule. The release maintains the pulsatile GH profile.
Such innovations are driving change across adjacent industries too. Discover more in our Rare Disease Drug Market.
4. Key Market Opportunity
A significant commercial opportunity in the Growth Hormone market comes from weekly long-acting growth hormone market displacement of daily injections, where the adherence and quality of life advantages drive prescribing transitions across pediatric and adult GHD. Pfizer-OPKO, Ascendis Pharma, and Novo Nordisk competing in long-acting GH capture this transition opportunity. Another growth driver centers on indication expansion to non-GHD short stature conditions. As long-acting GH adoption proceeds and indication expansion advances, the addressable opportunity is evolving from daily-injection-dominant GH treatment toward weekly long-acting GH across expanded indications.
5. Top Companies in the Growth Hormone Market
The following organisations hold leading positions in the Growth Hormone Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Novo Nordisk
- Pfizer
- Merck KGaA
- Eli Lilly
- Sandoz
- Ipsen
- Ferring Pharmaceuticals
- Ascendis Pharma
- LG
- BioMarin Pharmaceutical
6. Market Segmentation
The Growth Hormone Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Formulation | Daily Injection Weekly Long-Acting |
| By Drug | Somatropin Somapacitan Lonapegsomatropin Somatrogon |
| By Indication | Pediatric GHD Adult GHD Short Stature Turner Syndrome |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Growth Hormone Market trajectory over the forecast period:
Once-Weekly Somapacitan Ngenla Phase III REAL Non-Inferior Height Velocity Versus Daily Norditropin Reducing Injections From 365 to 52 Per Year Has Provided the Weekly Growth Hormone Alternative That Patient Preference and Adherence Advantage Support Over the Daily Injection Burden.Ascendis Pharma's Skytrofa weekly prodrug demonstrated non-inferior height velocity to daily somatropin at 52 weeks with superior adherence rates of 97% weekly versus 75-85% for daily injection in REAL4 registry data, establishing the first once-weekly somatropin approved for paediatric growth hormone deficiency. The TransCon growth hormone technology attaches somatropin to a carrier through a pH-sensitive linker that releases active GH over seven days from a single subcutaneous depot, achieving flat pharmacokinetics that mimic the physiological GH concentration profile more closely than daily injection's supraphysiological peaks and trough nadirs. The adherence advantage is particularly significant in paediatric GHD where the 4-7 years of daily injection until final height creates substantial injection burden that reduces compliance and ultimately compromises height outcomes in a meaningful fraction of treated children.
Pegvisomant Somavert GH Receptor Antagonist 97 Percent IGF-1 Normalisation in Acromegaly Patients Who Do Not Achieve Control With Somatostatin Analogue Alone Has Established the Peripheral GH Blockade as the Add-On or Alternative for the Somatostatin-Resistant Somatotroph Adenoma.Novo Nordisk's somapacitan Sogroya received FDA approval for adult growth hormone deficiency based on REAL4 trials demonstrating non-inferior IGF-1 normalisation to daily somatropin, establishing the once-weekly GH category in the adult indication where daily injection adherence challenges are particularly pronounced in working-age adults. The adult GHD population requiring somatropin replacement is smaller than the paediatric population but has fewer treatment alternatives, creating a commercially defensible premium-priced category for weekly formulations in the adult replacement indication. Somapacitan's non-inferiority in IGF-1 normalisation rather than height velocity outcomes distinguishes the adult GHD development programme from paediatric programmes, reflecting the different endpoints required for adult replacement where metabolic and body composition outcomes rather than linear growth define therapeutic success.
TransCon Lonapegsomatropin Prodrug Transient Connector Weekly Release of Native GH PATHFINDER Phase III Non-Inferior Height Velocity Has Provided the Once-Weekly Prodrug Approach That Maintains Pulsatile GH Profile From the Sustained-Release Mechanism.Eiger BioPharmaceuticals's lonafarnib demonstrated 2.5-month extension of median survival in progeria patients in the Progeria Research Foundation trial, earning accelerated FDA approval in the first therapy for this ultra-rare premature aging syndrome that involves defective processing of the progerin protein that accumulates in vascular and cardiac cells. The survival extension in a disease with median death at 14.5 years due to cardiovascular complications of accelerated atherosclerosis represents a clinically meaningful outcome in an indication affecting fewer than 400 children worldwide. The commercial challenge in progeria is defining a sustainable pricing model for a drug that treats under 100 children annually in the US while recovering the development investment, and the orphan drug tax credit and rare paediatric disease priority review voucher programme have been critical enablers of the programme's commercial viability.
For related market intelligence, see the Endocrinology Drug Market.
8. Segmental Analysis
By drug, the daily somatropin segment dominated the Growth Hormone Market in 2025, as established recombinant therapies from Novo Nordisk, Pfizer, and Merck KGaA anchored treatment of paediatric and adult growth hormone deficiency, generating the largest share of category revenue across endocrinology practice.
By formulation, the long-acting weekly segment is projected to register the highest growth rate through 2034, as Ascendis Pharma's Skytrofa and Novo Nordisk's weekly somapacitan improve adherence over daily injections and shift the treated population toward more convenient sustained-release dosing.
9. Regional Analysis
Regional demand patterns across the Growth Hormone Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Growth Hormone Market in 2025, accounting for approximately 46% of global revenue, due to US premium pricing for weekly long-acting growth hormone Skytrofa and Ngenla and the broad pediatric GHD treatment population. Moreover, weekly long-acting GH adoption is most advanced in the US. In addition, adult GHD therapy use is established. Regional dominance is attributed to this combination of pricing environment and weekly GH transition.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Growth Hormone Market through 2034, driven by the large pediatric GHD patient population in China, Japan, and South Korea and expanding access to both daily and weekly long-acting growth hormone formulations. The region is also witnessing weekly long-acting GH adoption growing. Moreover, GHD diagnosis is expanding. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Growth Hormone Market was valued at USD 5.44 Bn in 2025 and is projected to reach USD 10.18 Bn by 2034, growing at a CAGR of 7.2% over the 2026–2034 forecast period.
The Growth Hormone Market is projected to grow at a CAGR of 7.2% from 2026 to 2034.
North America dominated the Growth Hormone Market in 2025, accounting for approximately 46% of global revenue, due to US premium pricing for weekly long-acting growth hormone Skytrofa and Ngenla and the broad pediatric GHD treatment population.
The leading companies in the Growth Hormone Market include Novo Nordisk, Pfizer, Merck KGaA, Eli Lilly, Sandoz, Ipsen, Ferring Pharmaceuticals, Ascendis Pharma, LG, BioMarin Pharmaceutical.
Once-weekly somapacitan ngenla phase iii real non-inferior height velocity versus daily norditropin reducing injections from 365 to 52 per year has provided the weekly growth hormone alternative that patient preference and adherence advantage support over the daily injection burden.
By drug, the daily somatropin segment dominated the Growth Hormone Market in 2025, as established recombinant therapies from Novo Nordisk, Pfizer, and Merck KGaA anchored treatment of paediatric and adult growth hormone deficiency, generating the largest share of category revenue across endocrinology practice.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.